MTL & GRIP Collaborate to Develop Cutting Edge Biosensor Device

Molecular Testing Labs and GRIP Molecular Technologies have partnered to progress a cutting-edge electronic biosensor device that recently underwent a viability trial and yielded positive results.   

The single-use detection device uses medical information provided by the individual for diagnostic testing, displays findings on their mobile phone, and additionally forwards the outcomes to medical specialists.   

This makes it possible to diagnose illnesses quickly and provide appropriate treatment via an online system.  

Adam Blackwell, a leading member of MTL, stated, “We are committed to developing and offering new technologies that improve health, enhance healthcare experiences, and reduce costs in ways not possible with currently commercialised technologies.”  

Bruce Batten, the leading executive of GRIP, commented, “Evidence shows the prompt application of appropriate therapy is important to maximise its beneficial impact, and typically this is within 48 hours of symptom onset when many home-based diagnostics provide concerningly low levels of accuracy, leading to diagnosis delays.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.